Also known as EIDD-2801 or MK-4482. KEI Blogs 2021. October 22. Countries included in the Merck/molnupiravir license. 2021. October 20. International landscape of molnupiravir patents. 2021. October 4. U.S. Government’s $1.2 Billion Contract for Merck’s Investigational COVID-19 Drug Molnupiravir Redacts… Continue Reading →
On Tuesday, 5 October 2021, Knowledge Ecology International delivered the following opening statement at the 2021 WIPO General Assembly. General Statement of Knowledge Ecology International – WIPO General Assembly 5 October 2021 The COVID pandemic illustrates flaws in the intellectual… Continue Reading →
(For more resources, please see our page on molnupiravir.) Knowledge Ecology International (KEI) has obtained a copy of the $1.2 billion contract between the U.S. government and Merck to advance purchase 1,696,629 treatment courses of molnupiravir, an investigational COVID-19 drug… Continue Reading →
(For more resources, please see our page on molnupiravir.) Molnupiravir, the oral pill that is showing promising results as a potential treatment for covid-19, was invented at Emory University with U.S. government funds. After more than six years of non-clinical… Continue Reading →
On October 1, 2021, the WHO published the new edition of its Model Lists (the EML) of Essential Medicines and Essential Medicines for Children. WHO Documents Press Release Executive Summary World Health Organization model list of essential medicines: 22nd list… Continue Reading →
On September 27, 2021, Knowledge Ecology International (KEI) submitted the following comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent License: Chimeric Live-Attenuated Vaccine for West Nile Virus (WNV)” (86 FR 50722). The technology… Continue Reading →
KEI will host a two hour virtual roundtable on march-in rights in U.S. government-funded inventions on Wednesday October 6, 2021 from 2pm to 4pm EDT. This will take place via Zoom, so if you would like to take part in… Continue Reading →
In the wake of the damage wrought by the COVID-19 pandemic, the World Health Organization’s World Health Assembly established a Working Group on Strengthening WHO Preparedness and Response to Health Emergencies (WGPR) in May 2021 with the following mandate: to… Continue Reading →
On September 9, 2021, the Secretary of HHS, Xavier Becerra, pushed a 29 page report on proposals to address high drug prices. “Report To The White House Competition Council, on Comprehensive Plan for Addressing High Drug Prices. A Report in… Continue Reading →
PDF version of letter to NIH. Failure2disclose-Doudna-patents-12oct2020 October 12, 2020 Michelle Bulls Director Office of Policy for Extramural Research Administration (OPERA) National Institutes of Health Via Email: michelle.bulls@nih.gov RE: Failures to disclose government funding associated with patents related to “Methods… Continue Reading →